Clinical Researchers Adapting To Mandate For More Diversity In Study Populations

WASHINGTON -- Clinical investigators trying to include more women and minorities in their studies must rethink the traditional researcher-subject relationships and pay more attention to the needs of populations. And while the immediate costs of complying with federal mandates for increasing the use of underrepresented populations as research subjects may be significant, the long-term consequences of not doing so may be considerable, they say. "When I sit on committees, I hear members of re

Written byMarcia Clemmitt
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

"When I sit on committees, I hear members of renowned research institutions stressing the need to carefully separate research from service," says Janet Mitchell, director of the special prenatal clinic at Harlem Hospital in New York. "That's the old thinking: research has to be isolated and protected. But that won't hold water with these new populations."

Mitchell says today's researchers must be able to show how their science contributes to clients' welfare in addition to increasing the world's storehouse of knowledge. " Women, drug users, minorities--they're more sophisticated than the research establishment gives them credit for," says Mitchell. "Their question is, `What are you giving in return? I'm interested in helping if you show me how it'll help me or my children. If you only want me to get your data and your funds, I'm not coming.' " Critics of the use of homogeneous study populations in clinical research charge ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies